"We are pleased that this medical center selected the IOPtiMate™ system as its glaucoma surgery solution. This milestone conveys further confidence in our unique technology from the ophthalmology community and, along with our recent first sale in Hong Kong and our launch in China, demonstrates our ability to become a truly global player in this marketplace," said Suzana Nahum-Zilberberg, BioLight's chief executive officer.
News 
Market Data 
Discover 
AI
